Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;12(4):4294-4305.
doi: 10.1002/cam4.5299. Epub 2022 Oct 29.

Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity

Kou Kanesada  1 , Ryouichi Tsunedomi  1 , Shoichi Hazama  1 , Hiroyuki Ogihara  2 , Yoshihiko Hamamoto  2 , Yoshitaro Shindo  1 , Hiroto Matsui  1 , Yukio Tokumitsu  1 , Shin Yoshida  1 , Michihisa Iida  1 , Nobuaki Suzuki  1 , Shigeru Takeda  1 , Tatsuya Ioka  3 , Hiroaki Nagano  1
Affiliations

Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity

Kou Kanesada et al. Cancer Med. 2023 Feb.

Abstract

Objective: Irinotecan is a useful anticancer drug for colorectal cancer treatment. UGT1A1*28 and *6 gene polymorphisms are known risk factors for irinotecan-associated toxicity. However, severe adverse effects due to irinotecan have been observed even in patients who do not harbor UGT1A1*28 or *6. We investigated gene polymorphisms in the whole exome to identify useful biomarkers for irinotecan toxicity other than UGT1A.

Methods: A total of 178 patients with metastatic colorectal cancer (mCRC) and 87 patients with pancreatic cancer were treated with FOLFIRI, FOLFOX, FOLFOXIRI, modified FOLFIRINOX, or gemcitabine plus nab-paclitaxel. Genome-wide screening was performed using whole-exome sequencing (WES), and validation analysis was performed using qPCR with a hydrolysis probe.

Results: Using WES after a doublet chemotherapy regimen comprising irinotecan and 5-fluorouracil (n = 15), seven single nucleotide polymorphisms (SNPs) were identified as candidate biomarkers for irinotecan-associated toxicity of neutropenia. Among the seven SNPs, an SNP in R3H domain and coiled-coil containing 1 (R3HCC1; c.919G > A, rs2272761) showed a significant association with neutropenia (>grade 3) after doublet chemotherapy. Patients receiving irinotecan including triplet chemotherapy, FOLFOXIRI for mCRC (n = 23) or modified FOLFIRINOX for pancreatic cancer (n = 40), also showed significant linear trends between R3HCC1 polymorphism and neutropenia (p = 0.017 and 0.046, respectively). No significant association was observed in patients treated with irinotecan-free regimens, FOLFOX for mCRC (n = 66), and gemcitabine plus nab-paclitaxel for pancreatic cancer (n = 47).

Conclusion: Thus, an SNP in the R3HCC1 gene may be a useful biomarker for the toxicity of irinotecan-containing chemotherapy for mCRC and pancreatic cancer.

Keywords: R3HCC1; colorectal cancer; irinotecan; neutropenia; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Amino acid sequence of human R3HCC1. Human R3HCC1 (NP_001129580.2) comprises 440 amino acids. Positions 49–53 (blue text) and 318–382 (green text) are the RxxxH motif and RNA recognition motif (RRM) superfamily, respectively. The single nucleotide polymorphisms rs2272761 (p.Val307Met) and rs13530 (p.Leu363Arg) are represented by red boxes.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7‐34. - PubMed
    1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683‐691. - PubMed
    1. Saltz LB, Clarke S, Diaz‐Rubio E, et al. Bevacizumab in combination with oxaliplatin‐based chemotherapy as first‐line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013‐2019. - PubMed
    1. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med. 2000;343(13):905‐914. - PubMed
    1. Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second‐line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first‐line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double‐blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499‐508. - PubMed

Publication types

MeSH terms